When DCIS and IDC were compared, the T cell immunoglobulin and ITIM domain (TIGIT) co-inhibitory receptor was found to have higher expression in T cells from DCIS patients compared to HER2+ and TNBC IDC. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.